Pharma Stocks
-
Pfizer (PFE) Valuation Check As Shares Recover Modestly From Longer Term Weakness
Recent performance snapshot for Pfizer (PFE) Pfizer (PFE) has moved quietly higher in recent months, with a 1-month return of…
Read More » -
Astrazeneca Pharma India Ltd Faces Bearish Momentum Amid …
Technical Trend Overview The pharmaceutical giant’s technical trend has deteriorated from mildly bearish to outright bearish, reflecting increased selling pressure…
Read More » -
60 Degrees Pharma, Runway expand ARAKODA malaria access
60 Degrees Pharmaceuticals (NASDAQ: SXTP) announced a partnership with Runway Health to expand pre-departure access to ARAKODA® (tafenoquine) for malaria…
Read More » -
How BridgeBio’s (BBIO) Convertible Notes and Attruby Uptake Have Changed Its Investment Story
In January 2026, BridgeBio Pharma, Inc. completed a US$550,000,000 Rule 144A offering of 0.75% senior unsecured convertible notes due February…
Read More » -
How Investors May Respond To Royalty Pharma (RPRX) Dividend Hike Amid Insider Sales And Results Countdown
Royalty Pharma plc recently raised its quarterly dividend for the first quarter of 2026 to US$0.235 per Class A ordinary…
Read More » -
J&J Forecasts $100 Billion Milestone for 2026 as Trump Drug Pricing Deals Reshape the Pharma Landscape
NEW BRUNSWICK, N.J. — In a landmark display of resilience and strategic pivoting, Johnson & Johnson (NYSE: JNJ) reported fourth-quarter…
Read More » -
Defensive pharma heavyweight tests investors’ patience as Wall Street edges cautiou
GSK’s U.S.-listed ADR has slipped over the past week yet still sits comfortably above its 12?month lows, leaving investors torn…
Read More » -
Samrat Pharmachem Ltd Stock Hits 52-Week Low Amidst Conti…
Recent Price Movement and Market Context On the day in question, Samrat Pharmachem’s stock recorded an intraday low of Rs.206,…
Read More » -
Another alliance of health care and AI signals why pharma stocks could be back
Bristol Myers Squibb and Microsoft ‘s new partnership aimed at accelerating early detection of lung cancer marks the latest way…
Read More » -
CorMedix vs. Mirum Pharma: Which Rare-Disease Stock is the Better Buy? – January 20, 2026
Key Takeaways Mirum Pharmaceuticals shows a clearer growth narrative with multiple revenue drivers beyond Livmarli. CRMD’s outlook is clouded by…
Read More »